How do I hire an interim CRO for a biotech company in 2027?

Signals you actually need this

Most biotech founders reach for an interim revenue leader about six months later than they should, and usually for the wrong reason. The trigger that matters is not "sales are slow" — sales in this sector are structurally slow — it is that nobody in the building can explain *why* a specific deal is stalled in terms the board can act on. If your last three pipeline reviews ended with the phrase "they're still evaluating," you have a diagnostic problem, not a hustle problem, and that is exactly what an interim leader is built to solve.

Here are the concrete signals, in rough order of how often they show up in a diagnostics or life-science-tools company:

Founder-led sales has hit its ceiling. The scientific founder closed the first eight customers because those customers were peers who already trusted the science. Customer nine is a procurement officer at a hospital system who has never heard of your PI, wants a security questionnaire, a W-9, a certificate of insurance, and a reference from a comparable institution. The founder cannot scale that motion and, more importantly, should not be spending forty hours a week on it while the assay roadmap slips.

Your forecast is decoration. A working biotech forecast has stage definitions tied to observable buyer behavior — a signed evaluation agreement, a completed on-site validation run, a purchase requisition entered into the customer's ERP. If your CRM stages are "Interested / Very Interested / Verbal Yes," your forecast is a mood ring. An interim CRO's first deliverable is usually replacing those stages with exit criteria a skeptical CFO would accept.

You just raised, and the deck promised a commercial team. Series A and B decks in this sector routinely include a hiring plan with a VP Sales, two AEs, a field application scientist, and a marketing hire. Executing that plan badly costs 12 to 18 months and roughly $1.2M to $2M in fully-loaded comp before anyone realizes the ICP was wrong. An interim leader for six months at a fraction of that cost de-risks the sequence: define the motion, prove it works with one or two sellers, *then* hire the permanent VP into a system that exists.

Your VP Sales left and the pipeline is a black box. This is the classic interim use case and it is not unique to biotech — it looks the same in medical devices, industrial instrumentation, and regulated fintech. Someone has to hold the number, run the weekly cadence, and keep the team from unraveling while you run a four-to-six-month executive search. That is a bridge role, and it is a legitimate one.

Reimbursement or regulatory status just changed. A new CPT code, a 510(k) clearance, a CE mark under IVDR, or a CLIA lab going live changes who you can sell to and what you can claim. Commercial strategy has to be rewritten inside of a quarter, and most early teams have never done that rewrite before.

The channel question is unanswered. You are being courted by a distributor, or a GPO contract just came into view, and nobody internally can model whether giving up 25 to 40 points of margin buys enough reach to be worth it. That is a single high-stakes decision worth an experienced outside brain even if you need nothing else.

Counter-signal, and it matters: if your product has not cleared the regulatory or validation gate that lets a customer legally buy it, do not hire a revenue leader yet. No CRO can sell a device that cannot ship. Spend the money on the regulatory consultant instead and revisit in two quarters.

What good looks like vs. bad

The failure mode in this hire is almost never a lack of credentials. It is a mismatch between a candidate's actual operating experience and the motion your company needs. A leader who scaled a horizontal SaaS product from $5M to $40M ARR on inbound demand and two-week trials has genuinely impressive numbers and almost no transferable instinct for a 26-month capital-equipment sale with a scientific bake-off in the middle of it.

Good looks like a candidate who, unprompted, asks about your evidence base. Do you have peer-reviewed publications? Poster presentations at a relevant conference? Named KOLs willing to speak on record? A completed head-to-head against the incumbent method? Those are the assets that actually move a regulated purchase, and someone who has done this before will inventory them in the first conversation. Bad looks like a candidate whose first questions are all about your CRM stack and quota model — real questions, but downstream ones.

Good looks like specificity about the buying committee. In a hospital or reference lab purchase you are typically navigating a lab director (technical champion), a pathologist or medical director (clinical sign-off), a lab manager (workflow and staffing impact), supply chain or value analysis (contract and price), IT or informatics (LIS integration), and sometimes a capital committee that meets quarterly. A strong candidate names those roles from memory and tells you which one usually kills deals. In pharma R&D the committee shifts — a bench scientist champion, a procurement category manager, a sourcing lead operating under a master services agreement, and often a global preferred-vendor list you must get onto before you can transact at all. Bad looks like "we'll map the stakeholders in discovery."

Good looks like honesty about time-to-impact. The right answer to "when will revenue move?" is a version of: *bookings won't move much for two quarters because the cycles predate me; what will move in 90 days is pipeline hygiene, stage-exit discipline, forecast accuracy, and win/loss clarity.* Bad looks like a promise of a revenue spike in one quarter, which in practice is delivered through discounting, pulling forward deals that would have closed anyway, or stuffing the pipeline with unqualified opportunities that unwind after the engagement ends.

Good looks like references you can actually reach. Ask for three CEOs or board members who hired this person into an interim or fractional seat, and ask those references one specific question: *what did they change in the first 60 days, and did it survive after they left?* Durability is the whole test. Plenty of interim leaders create motion that evaporates the day the contract ends because it lived in their head instead of in a documented process.

Bad also looks like the portfolio problem. Some fractional operators carry five or six clients simultaneously. That is fine for advisory work and disqualifying for a role that requires attending your Monday pipeline review, joining a customer escalation on Wednesday, and prepping a board update on Thursday. Ask directly how many active engagements they hold and what their hard cap is. A credible answer for a 3-day-per-week seat is two clients, maybe three.

Real cost and ROI ranges

Pricing in this market is negotiated per engagement and varies widely by geography, stage, and scope, so treat any single number you hear as an anchor rather than a rate card. What you *can* control is the structure, and structure is where founders lose or save the most money.

Price by days, not by title. Nearly every interim and fractional revenue leader prices off a day rate, then multiplies by committed days per month. A two-day-per-week engagement is roughly eight to nine billable days a month; four days a week is sixteen to eighteen. Ask for the day rate explicitly and do the arithmetic yourself, because a "monthly retainer" quoted without a day count is impossible to compare across candidates. When you renegotiate at month three, you are usually adjusting the day count, not the rate.

Understand the full-time comparison honestly. A permanent CRO at a Series B biotech carries base salary, target bonus, equity, payroll taxes, benefits, and — if you use one — a search firm fee typically running 25 to 33 percent of first-year cash compensation. Add the ramp: a permanent hire is rarely productive before month four. The interim comparison is not "retainer vs. base salary." It is "retainer for six months" vs. "search fee plus four months of unproductive full-time comp plus the severance risk if the hire is wrong." Framed that way, interim frequently wins on pure expected cost even before you count the option value of learning what the role actually needs.

Budget for the wrapper, not just the leader. An interim CRO who cannot execute alone is an expensive strategist. Plan for the supporting spend in the same breath: a CRM administrator or RevOps contractor to actually rebuild stages and reporting, a marketing or content resource to produce the application notes and comparison data the sales motion needs, conference and travel budget for the two or three shows where your buyers actually congregate, and often a data or list source for the target account universe. Under-funding the wrapper is the single most common way this hire fails to produce a return.

Equity is the exception, not the rule. At pre-seed and seed, some operators will trade a portion of cash for a small option grant on standard vesting with a cliff. It happens, and it can be the right deal when cash is genuinely the binding constraint. It is uncommon at Series A and later, and you should be mildly suspicious of a candidate who pushes hard for equity in a short interim seat — the incentive horizon doesn't match a six-month mandate.

How to actually measure ROI in a sector where revenue lags. This is the part most boards get wrong. If you judge a six-month engagement on bookings alone, you will conclude it failed even when it succeeded, because the deals it influenced close after it ends. Instead, instrument the leading indicators the engagement is genuinely accountable for:

• *Qualified pipeline coverage* against the next four quarters' plan, measured with the new stage definitions, not the old ones.
• *Stage conversion rates*, specifically the evaluation-to-purchase-requisition step, which is where regulated deals die.
• *Forecast accuracy* — did the 90-day commit call land within a defensible band? Two clean quarters of accurate forecasting is worth more to your Series C than one lucky quarter of overperformance.
• *Cycle-stage duration*, especially time from first meeting to signed evaluation agreement, which is the one segment of a long cycle you can genuinely compress.
• *Win/loss documentation* — a real loss review on every closed-lost deal above a threshold, with the reason coded consistently. Ten of these are worth more strategically than any single win.
• *Durable artifacts* — the ICP definition, the pricing framework covering academic, core-facility, and pharma tiers, the qualification checklist, the discovery guide, the objection library, and the board reporting pack. These are the things that outlive the contract.

Structure the contract to protect both sides. Three months initial, renewable in three-month increments, 30-day notice from either party. Invoicing monthly in arrears against a stated day count. A clear IP clause assigning everything they build to the company. A carve-out that lets you pause for 60 days if a financing slips — experienced operators in this sector understand fundraising volatility and will usually agree. Avoid success fees tied to closed bookings in a long-cycle business; they distort behavior toward discounting and toward deals that were closing anyway. If you want variable comp, tie it to the leading indicators above or to a defined deliverable like a completed win/loss study.

Where to source candidates. Your existing investors are the highest-yield channel by a wide margin — biotech and life-science VCs keep informal benches of operators they have seen perform, and a referral comes pre-vetted with a real reference attached. Beyond that: revenue-leader communities such as Pavilion, RevOps-focused communities, sector-specific groups on LinkedIn, executive search firms that run interim practices, and the boards of comparable companies in adjacent modalities. Search LinkedIn by the *motion* rather than the title — "capital equipment," "clinical diagnostics sales," "life science tools," "CDMO business development" — because the people you want often held VP Commercial or Chief Commercial Officer titles rather than CRO.

How it plugs into your workflow

An interim CRO who operates outside your existing systems produces a beautiful deck and no durable change. The engagement has to be wired into the same rhythms your RevOps function, your board, and your scientific team already run on. Here is the integration sequence that works, and the adjacent functions each step touches.

Week one: access before opinions. Give them full CRM access, read access to the finance model, the last four board decks, every closed-won and closed-lost record, the current pricing sheet, the regulatory status summary, and the roadmap. Add them to the exec staff meeting and the pipeline review as an observer. Do not have them present anything in week one. A leader forming conclusions before seeing the loss data is guessing.

Weeks one through four: the diagnostic. They interview every seller, the field application scientists, customer success or technical support, marketing, and — critically — three to five recent customers and two lost prospects. The customer interviews are the highest-signal part and the most often skipped. Output is a written diagnostic: current stage definitions and where they break, conversion by stage, deal size distribution, ICP as observed versus as claimed, competitive positioning against the actual alternative (which is frequently "the customer's existing manual method," not a named competitor), and a prioritized gap list.

Weeks five through eight: rebuild the operating layer. This is where the RevOps overlap is heaviest, and where you should expect them to work alongside whoever owns your systems. Concretely: rewrite CRM stages with objective exit criteria; build a qualification framework adapted for regulated buying — most teams end up with something MEDDIC-shaped plus explicit fields for regulatory gate, funding source (grant, capital budget, operating budget, or study-specific), and validation requirement; construct a pricing architecture with defensible tiers across academic, core facility, reference lab, and pharma; produce a discovery guide and objection library grounded in the loss data. Every artifact goes into a shared repository, not into their laptop.

Weeks nine through twelve: run the cadence and hand over. Weekly pipeline review with the new stages. Monthly forecast call with a committed number and a documented methodology. A board reporting pack that shows leading indicators alongside bookings. Simultaneously, they should be helping you write the job description for the permanent leader — because a good interim engagement makes itself replaceable, and the spec for the permanent hire should be written *after* the motion is understood, not before.

Adjacent functions this touches, and how to keep them from colliding. Marketing needs to shift from brand-style content to evidence content — application notes, protocols, validation data, comparison studies — and the interim leader should be dictating that priority list. Product and R&D will receive a stream of field requirements; route those through a single documented intake rather than letting the CRO lobby the CTO directly. Regulatory and quality need visibility into every claim the sales team makes, and a claims-review checkpoint prevents a very expensive class of mistake. Finance owns the pricing floor and the discount approval matrix; the CRO proposes, finance approves. Customer success or field application scientists usually need their role redefined from "post-sale support" to "pre-sale technical proof," which is one of the higher-leverage changes available in this sector.

The same pattern works outside biotech. Medical device, industrial instrumentation, defense hardware, clinical software, and regulated financial services all share the core shape: long cycles, committee buying, compliance gates, and a technically credible champion who does not control budget. If you are evaluating a candidate from one of those adjacent verticals rather than biotech proper, the transfer is usually clean as long as they have operated under a real compliance regime. What does not transfer is velocity-driven, product-led, self-serve motion — that is a genuinely different job.

Related questions

Should I hire an interim CRO or a VP Sales first?

If nobody has defined the motion, hire the interim leader first — a VP Sales inherits a system rather than inventing one. If the motion is proven and you simply need execution capacity, skip straight to a VP Sales or two account executives and save the retainer.

How long should a biotech interim CRO engagement run?

Three months minimum to complete a real diagnostic and rebuild, six to nine months typical, twelve at the outer edge. Beyond twelve months you are paying interim rates for a permanent function. Renew in three-month increments so scope stays deliberate.

Can one person cover both commercial strategy and RevOps systems work?

Rarely well. Most interim CROs design the process but need an administrator or RevOps contractor to implement it in Salesforce or HubSpot. Budget for both. Expecting an executive to build reports and clean data wastes an expensive day rate.

What should the first board update from an interim CRO contain?

The diagnostic findings, revised stage definitions with conversion rates, a corrected pipeline number under the new stages (usually smaller — that is a feature), the top three structural gaps, and a 90-day plan with leading-indicator targets rather than a bookings promise.

Does the same approach work for a CDMO or a contract research organization?

Largely yes. CDMO and CRO services businesses share the long cycle, committee buying, and technical-champion dynamic. The main difference is capacity-driven pricing and master-service-agreement gating, so weight candidates who have sold recurring services rather than instruments.

FAQ

What is the difference between an interim CRO, a fractional CRO, and a consultant?

An interim CRO fills a vacant seat full-time for a defined period and holds the number, the team, and the board relationship. A fractional CRO does the same job at a reduced day count, usually two to four days a week, often across two clients. A consultant delivers analysis and recommendations without owning outcomes or managing people. For a biotech company that needs the motion built and run, you want one of the first two — the consultant model leaves you with a document and no operator.

How do I evaluate biotech domain expertise if I am not a commercial person myself?

Bring your most experienced commercial-adjacent person into the interview — a board member, an investor, or a field application scientist who has sat through purchases. Then use behavioral questions with verifiable specifics: which regulatory gate blocked a deal, how they got a product onto a hospital's approved-vendor list, how they handled a GPO or distributor negotiation. Vague answers to specific questions are the disqualifier. Follow up with references and ask each one what changed and whether it stuck.

Is it realistic to expect revenue growth within the engagement?

Expect pipeline quality, forecast accuracy, and process discipline to improve inside 90 days. Expect bookings to move on the natural cycle length of your business, which in diagnostics and life-science tools commonly means two to four quarters out. Any candidate promising a fast bookings jump is describing discounting or pull-forward, both of which cost you margin and create an air pocket the quarter after they leave.

Should the interim CRO be involved in hiring their permanent replacement?

Yes, and it is one of the most valuable things they do. After ninety days of operating your motion they can write a job description grounded in reality rather than aspiration, screen candidates on the dimensions that actually predict success here, and hand over documented process. Build that explicitly into the mandate rather than treating it as a favor.

What happens to the work if the engagement ends early?

This is why the artifacts matter more than the person. Require that every deliverable — stage definitions, qualification criteria, pricing framework, playbook, board pack template, win/loss database — lives in your systems and your document repository from the day it is created. Add an IP assignment clause to the contract. With a 30-day notice period and artifacts in place, an early exit costs you continuity, not knowledge.

Do I need someone local, or does remote work for this role?

Remote works for the majority of the mandate. What genuinely requires presence is customer visits, conference attendance, and the first few weeks of team immersion. A common structure is remote by default with two to four on-site or field days a month, plus the trade shows where your buyers actually gather. Budget travel separately rather than folding it into the day rate.

Sources

• U.S. Food and Drug Administration — Medical Devices
• Centers for Medicare & Medicaid Services — CLIA
• National Institutes of Health — Grants and Funding
• European Commission — In Vitro Diagnostic Medical Devices Regulation
• Harvard Business Review
• MIT Sloan Management Review
• First Round Review
• Pavilion — Community for Revenue Leaders
• ISO 13485 — Medical Devices Quality Management
• Nature Biotechnology

Related on PULSE

• [How do I hire a fractional CRO for a medical device company in 2027?](/knowledge/tl9705)
• [What does a fractional CRO actually do in the first 90 days?](/knowledge/tl14291)
• [Where do I find an interim CRO in Durham in 2027?](/knowledge/tl15485)
• [How do I build a sales forecast for a long enterprise sales cycle?](/knowledge/tl19472)
• [When should a startup hire a VP of Sales instead of a CRO?](/knowledge/tl20032)
• [How do I set up RevOps stage definitions that a board will trust?](/knowledge/tl9627)